Your browser is no longer supported. Please, upgrade your browser.
IKT [NASD]
Inhibikase Therapeutics, Inc.
Index- P/E- EPS (ttm)-0.55 Insider Own21.00% Shs Outstand10.05M Perf Week-2.92%
Market Cap61.19M Forward P/E- EPS next Y-0.69 Insider Trans0.00% Shs Float4.74M Perf Month-17.08%
Income-4.90M PEG- EPS next Q-0.38 Inst Own14.30% Short Float5.47% Perf Quarter-54.93%
Sales1.80M P/S33.99 EPS this Y43.30% Inst Trans107.33% Short Ratio0.35 Perf Half Y-68.08%
Book/sh0.80 P/B2.91 EPS next Y- ROA-69.30% Target Price- Perf Year-
Cash/sh0.37 P/C6.37 EPS next 5Y- ROE-251.10% 52W Range2.03 - 11.80 Perf YTD-66.23%
Dividend- P/FCF- EPS past 5Y- ROI-27.90% 52W High-81.02% Beta-
Dividend %- Quick Ratio3.30 Sales past 5Y- Gross Margin- 52W Low10.34% ATR0.22
Employees3 Current Ratio3.30 Sales Q/Q366.70% Oper. Margin- RSI (14)35.21 Volatility12.61% 9.40%
OptionableNo Debt/Eq0.15 EPS Q/Q-348.40% Profit Margin- Rel Volume0.76 Prev Close2.33
ShortableYes LT Debt/Eq0.03 Earnings- Payout- Avg Volume733.02K Price2.24
Recom- SMA20-9.60% SMA50-36.80% SMA200-58.79% Volume424,501 Change-3.86%
Jul-26-21 10:09AM  
08:42AM  
Jun-18-21 06:45PM  
Jun-16-21 08:00AM  
06:57AM  
Jun-15-21 07:40PM  
May-25-21 08:00AM  
May-17-21 04:05PM  
Apr-21-21 08:00AM  
Apr-01-21 08:00AM  
Mar-02-21 08:05AM  
Feb-22-21 08:05AM  
Feb-17-21 12:48PM  
08:05AM  
Jan-04-21 08:01AM  
Dec-28-20 10:33AM  
Dec-23-20 05:12PM  
Dec-22-20 06:25PM  
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia and neurogenic constipation; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects. It also develops IkT-01427, a product candidate that blocks the causative virus of progressive multifocal leukoencephalopathy from replicating in the body. The company has collaborations with The Johns Hopkins University; Louisiana State University School of Medicine, Shreveport; and Memorial Sloan-Kettering Cancer Center. The company was founded in 2008 and is headquartered in Atlanta, Georgia.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Werner Milton H.President and CEOMay 14Option Exercise0.3843,70716,6095,288,645May 18 05:46 PM